UCB 34714

This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12… (More)

The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide… (More)

BACKGROUND AND PURPOSE Screening of 12,000 compounds for binding affinity to the synaptic vesicle protein 2A (SV2A), identified a… (More)

BACKGROUND Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5-1.0% of the population. Many… (More)

Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It possesses a binding affinity for the synaptic… (More)

Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… (More)

In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… (More)

Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… (More)

(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently… (More)

The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the… (More)